Eflornithine

Brand names: Vaniqa
Drug class: Antineoplastic Agents , Antineoplastic Agents

Usage of Eflornithine

Because this drug is no longer available in the U.S. market, the material in this section is no longer updated by AHFS DI. If this drug is used in countries other than the U.S., it is essential that the manufacturers’ labeling be consulted for more recently available information.

Reduction of Unwanted Facial Hair

Reduction of unwanted facial hair in women.

Relate drugs

How to use Eflornithine

General

Because this drug is no longer available in the U.S. market, the material in this section is no longer updated by AHFS DI. If this drug is used in countries other than the U.S., it is essential that the manufacturers’ labeling be consulted for more recently available information.

  • Marked improvement may occur after 8 weeks of therapy. Hair growth usually returns to baseline levels 8 weeks after discontinuing therapy.

    • Administration

    Topical Administration

    Apply to skin as a 13.9% cream.

    Apply only to affected areas of the face and adjacent involved areas under the chin; not intended for oral, ophthalmic, or intravaginal use.

    Apply a thin film and rub in thoroughly.

    Do not wash treated areas for at least 4 hours after application.

    Continue hair removal techniques (e.g., plucking, tweezing, cutting, shaving), as needed, throughout treatment. Do not apply cream for at least 5 minutes after hair removal.

    May apply cosmetic products and sunscreens after cream has dried.

    Dosage

    Available as eflornithine hydrochloride; dosage expressed in terms of the salt.

    Adults

    Reduction of Unwanted Facial Hair Topical

    Apply a thin film twice daily at least 8 hours apart (or as directed by clinician).

    If skin irritation or intolerance develops, reduce application frequency to once daily. If irritation continues, discontinue therapy.

    Warnings

    Contraindications

  • Known hypersensitivity to eflornithine or any ingredient in the formulation.

    • Warnings/Precautions

    Warnings

    Because this drug is no longer available in the U.S. market, the material in this section is no longer updated by AHFS DI. If this drug is used in countries other than the U.S., it is essential that the manufacturers’ labeling be consulted for more recently available information.

    Sensitivity Reactions

    Hypersensitivity Reactions

    Discontinue therapy if hypersensitivity reactions occur.

    General Precautions

    Dermatologic Effects

    Possible transient stinging or burning if applied to abraded or broken skin.

    Skin irritation may occur in susceptible patients or in those using higher than recommended dosages.

    Specific Populations

    Pregnancy

    Category C.

    Lactation

    Not known whether eflornithine is distributed into milk. Caution if used in nursing women.

    Pediatric Use

    Safety and efficacy not established in children <12 years of age.

    Geriatric Use

    No substantial differences in safety relative to younger adults.

    Common Adverse Effects

    Burning, stinging, and/or tingling skin; erythema; rash.

    What other drugs will affect Eflornithine

    Because this drug is no longer available in the U.S. market, the material in this section is no longer updated by AHFS DI. If this drug is used in countries other than the U.S., it is essential that the manufacturers’ labeling be consulted for more recently available information.

    Not known whether topical eflornithine interacts with other topically applied drugs.

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords

    AI Assitant